Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-000603-91
    Sponsor's Protocol Code Number:CA013-004
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-06-17
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2016-000603-91
    A.3Full title of the trial
    A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination with N ivolumab (BMS-936558) in Subjects with Advanced Solid Tumors
    Studio di fase 1/2a di BMS-986179 somministrato in monoterapia e in combinazione con nivolumab (BMS-936558) in soggetti con tumori solidi in stadio avanzato

    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study of BMS-986179 Administered alone and in Combination with Nivolumab (BMS-
    936558) in Subjects with Advanced Solid Tumors
    Studio di BMS-986179 somministrato in monoterapia e in combinazione con nivolumab (BMS-936558) in soggetti con tumori solidi in stadio avanzato
    A.3.2Name or abbreviated title of the trial where available
    ooo
    ooo
    A.4.1Sponsor's protocol code numberCA013-004
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT02754141
    A.5.3WHO Universal Trial Reference Number (UTRN)U1111-1179-3950
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBristol-Myers Squibb International Corporation
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBristol-Myers Squibb International Corporation
    B.5.2Functional name of contact pointMilagros Blazquez
    B.5.3 Address:
    B.5.3.1Street AddressParc de l'Alliance - Avenue de Finlande, 4
    B.5.3.2Town/ cityBraine-l'Alleud
    B.5.3.3Post code1420
    B.5.3.4CountryBelgium
    B.5.4Telephone number0000000
    B.5.5Fax number0000000
    B.5.6E-mailclinical.trials@bms.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNIVOLUMAB - 10ml vial - clinical
    D.3.2Product code [BMS-936558]
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNIVOLUMAB
    D.3.9.1CAS number 946414-94-4
    D.3.9.2Current sponsor codeBMS-936558-01
    D.3.9.3Other descriptive nameBMS936558; BMS-936558, MDX1106, ONO-4538
    D.3.9.4EV Substance CodeSUB32944
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNIVOLUMAB - 4ml vial - clinical
    D.3.2Product code BMS-936558
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNIVOLUMAB
    D.3.9.1CAS number 946414-94-4
    D.3.9.2Current sponsor codeBMS-936558
    D.3.9.3Other descriptive nameBMS936558,BMS-936558, MDX1106, ONO-4538
    D.3.9.4EV Substance CodeSUB32944
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAnti-CD73
    D.3.2Product code [BMS-986179]
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAnti CD73
    D.3.9.2Current sponsor codeCA013-004
    D.3.9.3Other descriptive nameBMS986179
    D.3.9.4EV Substance CodeSUB181628
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number35
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Opdivo (100 mg/10 ml)
    D.2.1.1.2Name of the Marketing Authorisation holderBristol-Myers Squibb Pharma EEIG
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNIVOLUMAB - 10ml vial- COMMERCIAL
    D.3.2Product code [BMS-936558]
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNIVOLUMAB
    D.3.9.1CAS number 946414-94-4
    D.3.9.2Current sponsor codeBMS-936558-01
    D.3.9.3Other descriptive nameBMS936558; BMS-936558, MDX1106, ONO-4538
    D.3.9.4EV Substance CodeSUB32944
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Opdivo (40 mg/4 ml)
    D.2.1.1.2Name of the Marketing Authorisation holderBristol-Myers Squibb Pharma EEIG
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNIVOLUMAB - 4ml vial- COMMERCIAL
    D.3.2Product code [BMS-936558]
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNIVOLUMAB
    D.3.9.1CAS number 946414-94-4
    D.3.9.2Current sponsor codeBMS-936558
    D.3.9.3Other descriptive nameBMS936558,BMS-936558, MDX1106, ONO-4538
    D.3.9.4EV Substance CodeSUB32944
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Solid tumors
    Tumori solidi
    E.1.1.1Medical condition in easily understood language
    Solid tumors
    Tumori solidi
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10065252
    E.1.2Term Solid tumor
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective is to assess the safety and tolerability of BMS-
    986179 administered alone and in combination with nivolumab.
    Valutare la sicurezza e la tollerabilità di BMS-986179 somministrato in monoterapia e in combinazione con nivolumab
    E.2.2Secondary objectives of the trial
    -) To characterize the PD activity of BMS-986179 administered alone and
    in combination with nivolumab
    -) To assess the preliminary anti-tumor activity of BMS-986179 in
    combination with nivolumab as measured by ORR, DOR, and
    progression-free survival rate (PFSR)
    -) To characterize the PK and immunogenicity of BMS-986179
    administered alone and in
    combination with nivolumab
    -) To characterize the immunogenicity of nivolumab when administered
    in combination with
    BMS-986179
    • Caratterizzare la farmacodinamica (Pharmacodynamic, PD) di BMS-986179 somministrato in monoterapia e in combinazione con nivolumab
    • Valutare l’attività antitumorale preliminare di BMS-986179 in monoterapia e in combinazione con nivolumab misurata in base al tasso di risposta obiettiva (Objective Response Rate, ORR), durata della risposta (Duration of Response, DOR) e tasso di sopravvivenza libera da progressione (Progression-Free Survival Rate, PFSR)
    • Caratterizzare la farmacocinetica (Pharmacokinetics, PK) e l’immunogenicità di BMS-986179 somministrato in monoterapia e in combinazione con nivolumab
    • Caratterizzare l’immunogenicità di nivolumab somministrato in combinazione con BMS-986179
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives

    Pharmacogenetics
    Version: 6.0
    Date: 20/10/2017
    Title: A Phase 1/2a Study of BMS-986179 Administered alone and in
    Combination with Nivolumab (BMS- 936558) in Subjects with Advanced
    Solid Tumors.
    Objectives: Additional research samples and the data they generate are used by BMS researchers, and a variety of collaboration partners, to continue to explore the science behind both our drugs and the causes and mechanism of disease and how to effectively treat patients beyond the timeframe of the study, including their use in the development and/or validation of companion diagnostics to support the use of a particular therapy. These samples and their related data may also be used together with samples and data from other clinical studies to support this expanded research.

    Pharmacogenomics
    Version: 6.0
    Date: 20/10/2017
    Title: A Phase 1/2a Study of BMS-986179 Administered alone and in
    Combination with Nivolumab (BMS- 936558) in Subjects with Advanced
    Solid Tumors.
    Objectives: Additional research samples and the data they generate are used by BMS researchers, and a variety of collaboration partners, to continue to explore the science behind both our drugs and the causes and mechanism of disease and how to effectively treat patients beyond the timeframe of the study, including their use in the development and/or validation of companion diagnostics to support the use of a particular therapy. These samples and their related data may also be used together with samples and data from other clinical studies to support this expanded research.

    Other types of substudies
    Specify title, date and version of each substudy with relative objectives: Part 1B is a substudy

    Farmacogenetica
    Versione: 6.0
    Data: 20/10/2017
    Titolo: Studio di fase 1/2a di BMS-986179 somministrato in monoterapia e in combinazione
    con nivolumab (BMS-936558) in soggetti con tumori solidi in stadio avanzato, sezione 5.10 del protocollo

    Obiettivi: Questi campioni e i dati che saranno generati da questa ricerca addizionale saranno utilizzati dai ricercatori di BMS per continuare ad esplorare le caratteristiche dei farmaci B-MS -986179 e Anti-CD73, le cause e il meccanismo delle patologie in studio e come trattare efficacemente i pazienti oltre la durata dello studio, compreso il loro uso nello sviluppo e/o nella convalida di sistemi diagnostici per supportare l'uso di una particolare terapia. Questi campioni e i relativi dati potrebbero anche essere utilizzato insieme ai campioni e ai dati provenienti da altri studi clinici per ampliare questa ricerca.

    Farmacogenomica
    Versione: 6.0
    Data: 20/10/2017
    Titolo: Studio di fase 1/2a di BMS-986179 somministrato in monoterapia e in combinazione
    con nivolumab (BMS-936558) in soggetti con tumori solidi in stadio avanzato, sezione 5.10 del protocollo
    Obiettivi: Questi campioni e i dati che saranno generati da questa ricerca addizionale saranno utilizzati dai ricercatori di BMS per continuare ad esplorare le caratteristiche dei farmaci B-MS -986179 e Anti-CD73, le cause e il meccanismo delle patologie in studio e come trattare efficacemente i pazienti oltre la durata dello studio, compreso il loro uso nello sviluppo e/o nella convalida di sistemi diagnostici per supportare l'uso di una particolare terapia. Questi campioni e i relativi dati potrebbero anche essere utilizzato insieme ai campioni e ai dati provenienti da altri studi clinici per ampliare questa ricerca.

    Altre tipologie di sottostudi
    specificare il titolo, la data e la versione di ogni sottostudio con i relativi obiettivi: parte 1B è un sottostudio
    NOTA: ma non è applicabile in Italia

    E.3Principal inclusion criteria
    - Men and women at least 18 years of age
    - Advanced solid tumors
    - Eastern Cooperative Oncology Group (ECOG) 0-1
    - Acceptable lab testing results
    - Allow biopsies
    - Uomini e donne di almeno 18 anni di età;
    - Tumori solidi avanzati;
    - Eastern Cooperative Oncology Group (ECOG) 0-1
    - Risultati dei test di laboratorio accettabili
    - Consenso all’esecuzione di biopsie
    E.4Principal exclusion criteria
    - Central nervous system (CNS) tumors
    - Uncontrolled or significant cardiovascular diseases
    - Active or known autoimmune disease
    - Organ transplant
    - Tumori del sistema nervoso centrale (SNC)
    - Malattie cardiovascolari non sotto controllo o significative
    - Malattia autoimmune nota o attiva
    - Trapianto d'organo
    E.5 End points
    E.5.1Primary end point(s)
    The primary objective of the study is to assess the safety and tolerability
    of BMS-986179 administered alone and in combination with nivolumab.
    The assessment of safety will be based on the incidence of AEs, SAEs,
    AEs leading to discontinuation, and deaths in relation to initial
    treatment. In addition, clinical laboratory test abnormalities will be
    examined.
    L’obiettivo primario è valutare la sicurezza e la tollerabilità di BMS-986179 somministrato in monoterapia e in combinazione con nivolumab. La valutazione della sicurezza sarà basata sull'incidenza di AE, SAE che determineranno la sospensione del trattamento e ai decessi in relazione al trattamento iniziale. Inoltre, saranno valutate le anomalie cliniche nei test di laboratorio.
    E.5.1.1Timepoint(s) of evaluation of this end point
    see above section
    Vedi la sezione di cui sopra
    E.5.2Secondary end point(s)
    The first secondary objective (PD effect of CD73 inhibition) will be
    measured by CD73 enzyme assays and CD73 IHC in pre- and ontreatment
    tumor biopsies.
    The anti-tumor activity of BMS-986179 in combination with nivolumab
    will be measured by ORR, DOR, and PFSR at 24 weeks and will be based
    on RECIST 1.1 for solid tumors. These anti-tumor assessments may also
    be performed periodically on an exploratory basis after the 24-week time
    point as warranted by the data. Disease assessment with CT and/or MRI
    as appropriate will be performed at baseline, every 8 weeks from the
    start of combination treatment for the Q1W, Q2W and Q4W regimens, or
    every 9 weeks from the start of combination treatment for the Q3W
    regimen until treatment discontinuation or completion, and then every
    12 weeks for the first year until further disease progression, start of a
    new treatment, lost to follow-up, or death, whichever comes first.
    The PK will be characterized by assessment of PK parameters of BMS-
    986179, and immunogenicity will be assessed by the frequency of
    positive ADA to BMS-986179 and nivolumab.
    Il primo obiettivo secondario (effetto PD dell'inibizione di CD73) sarà misurato mediante l’analisi enzimatica CD73 e CD73 IHC sui campioni bioptici prima del trattamento e durante il trattamento dello studio.

    L'attività antitumorale di BMS-986179 in combinazione con nivolumab sarà misurata da ORR, DOR e PFSR a 24 settimane e sarà basata sul RECIST 1.1 per i tumori solidi. Queste valutazioni antitumorali potranno essere eseguite anche periodicamente su base esplorativa dopo le 24 settimane.

    La valutazione della malattia con TC e/o risonanza magnetica sarà eseguita al basale, ogni 8 settimane dall’inizio del trattamento di combinazione per i regimi Q1W, Q2W e Q4W o
    ogni 9 settimane dall'inizio del trattamento combinato per il regime Q3W fino alla sospensione o al completamento del trattamento, e poi per tutti i regimi ogni 12 settimane per il primo anno fino all'ulteriore progressione della malattia, inizio di un nuovo trattamento, perso al follow-up o alla morte, a seconda dell'evento che si verifica per primo.

    La PK sarà caratterizzata dalla valutazione dei parametri PK di BMS- 986179 e l'immunogenicità sarà valutata dalla frequenza di ADA positivo a BMS-986179 e nivolumab.
    E.5.2.1Timepoint(s) of evaluation of this end point
    see above section.
    Vedi la sezione di cui sopra
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans Yes
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    E.8.1.1 - Randomizzato E.8.1.2 - In aperto
    Randomised:, open
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA20
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    Israel
    United States
    France
    Germany
    Italy
    Netherlands
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LPLV
    LPLV
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days4
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months11
    E.8.9.2In all countries concerned by the trial days11
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 298
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 74
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state40
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 81
    F.4.2.2In the whole clinical trial 372
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    At the end of the study, BMS will not continue to provide BMS-supplied
    study drug to subjects/investigators unless BMS chooses to extend the
    study.
    Alla fine dello studio, BMS non continuerà a fornire i farmaci in studio, a meno che BMS scelga di estendere lo studio. Lo sperimentatore di ciascun centro dovrà assicurarsi che i pazienti partecipanti ricevano lo Standard of Care appropriato per trattare la loro malattia
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-03-14
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-12-20
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 04:35:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA